Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Evaluating the Performance of the IMPACT Model in the Prehospital TXA for TBI Trial
Neuro Trauma and Critical Care
P14 - Poster Session 14 (11:45 AM-12:45 PM)
1-001
The International Mission on Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury (IMPACT) prognostic model predicts functional outcome after moderate-severe traumatic brain injury (TBI). Our previous work suggested that glial fibrillary acidic protein (GFAP) may improve the discrimination of outcome when added to prognostic models.
To test the IMPACT model’s performance in a contemporary clinical trial population.

We analyzed data from a subset subjects from the phase II double-blind, multicenter randomized controlled trial, “Prehospital Tranexamic Acid Use for Traumatic Brain Injury.” This subset was limited to subjects in the placebo arm of the parent trial with evidence of hemorrhage on initial head computed tomographic (CT) scan. All 3 versions (core, extended, lab) of the IMPACT model were evaluated against 6-month mortality, plus an exploratory 4th version (lab+GFAP). We compared our results to previously published validation results from the CENTER-TBI cohort.

Within the subset (n=166), 127 subjects had complete 6-month outcome data. Predictor variables were missing <10% (0-9.4%) of cases, and were imputed (GCS motor score, pupillary reactivity, serum glucose, serum hemoglobin, hypoxia, and Marshall CT score). GFAP was associated with mortality (p=0.004). The core model discriminated poorly in the subset (AUC 0.60 [95% CI: 0.48-0.71], p=0.096). The extended model discriminated well (AUC 0.73 [95% CI: 0.64-0.82], p<0.001). The lab model discriminated non-significantly better (AUC 0.76 [95% CI: 0.66-0.86], p=0.167). Adding GFAP to the lab model improved discrimination further (AUC 0.83 [95% CI: 0.76-0.90], p=0.004). All 4 models overestimated mortality compared with the observed rate (n=31, 24% v. 26-82%).
In comparison with the observational CENTER-TBI validation cohort, the IMPACT models (core/extended/lab) discriminated mortality less well in a subset of the TXA trial. The addition of GFAP improved discrimination for mortality, but further work is needed to optimize its addition to the lab model.
Authors/Disclosures
H. E. Hinson, MD, MCR, FAAN (UCSF/Zuckerberg San Francisco General Hospital )
PRESENTER
Dr. Hinson has received personal compensation in the range of $0-$499 for serving as a Consultant for Rapid AI. Dr. Hinson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Hinson has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. Dr. Hinson has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association.
Shannon McWeeney Shannon McWeeney has nothing to disclose.
Adam Ferguson Adam Ferguson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Spine X Inc. Adam Ferguson has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuronasal Inc.. The institution of Adam Ferguson has received research support from NIH/NINDS. The institution of Adam Ferguson has received research support from VA RR&D. The institution of Adam Ferguson has received research support from VA BLR&D. The institution of Adam Ferguson has received research support from Wings for Life Foundation/Craig H Neilsen Foundation. The institution of Adam Ferguson has received research support from Wings for Life Foundation. The institution of Adam Ferguson has received research support from DoD/CDMRP. The institution of Adam Ferguson has received research support from DARPA. The institution of Adam Ferguson has received research support from DoE. Adam Ferguson has received personal compensation in the range of $500-$4,999 for serving as a Reviewer with NIH/CSR.
Martin Allan Schreiber, MD (OHSU) Dr. Schreiber has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for CSL Behring. Dr. Schreiber has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Harmonetics. Dr. Schreiber has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Tricol. Dr. Schreiber has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Trauma Textbook. Dr. Schreiber has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Lawyers. The institution of Dr. Schreiber has received research support from DoD.
Susan Rowell, MD, MCR Dr. Rowell has nothing to disclose.